Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.49 |
| ▸ | F3 | P13726 | 18/20 | 0.49 |
| ▸ | F2 | P00734 | 9/20 | 0.48 |
| ▸ | F10 | P00742 | 9/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422452 | 0.91 | F7 (0.51) | F7F3F2F10PRSS1 | |
| SCHEMBL8299398 | 0.89 | F7 (0.47) | F7F3F2F10PRSS1 | |
| SCHEMBL5882260 | 0.85 | F7 (0.58) | F7F3F2F10PRSS1 | |
| SCHEMBL8302861 | 0.83 | F7 (0.69) | F7F3F2F10PRSS1 | |
| SCHEMBL5044585 | 0.82 | F7 (0.75) | F7F3F2F10PRSS1 | |
| SCHEMBL5883507 | 0.80 | F10 (0.54) | F7F3F2F10PRSS1 | |
| SCHEMBL5882965 | 0.80 | F7 (0.56) | F7F3F2F10PRSS1 | |
| SCHEMBL5883280 | 0.80 | F7 (0.53) | F7F3F2F10PRSS1 | |
| SCHEMBL5883516 | 0.79 | F7 (0.51) | F7F3F2F10PRSS1 | |
| SCHEMBL5882658 | 0.79 | F7 (0.48) | F7F3F2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2004113278-A2 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIA | GENENTECH, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | TFPI, HABP2, TFPI2 | F7 4/4885F3 41/4885F2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.